18 September 2018 | News
Under the terms of the collaboration agreement Neurimmune conducts research to generate and validate human-derived monoclonal antibodies using its proprietary Reverse Translational Medicine™ (RTM™) technology platform
Neurimmune has announced the achievement of a key preclinical milestone in the ongoing collaboration with Ono Pharmaceutical Co., Ltd. In November 2017, the parties entered into a collaboration focused on the development of human-derived antibodies against a novel therapeutic target for neurodegenerative diseases.
Under the terms of the collaboration agreement, Neurimmune conducts research to generate and validate human-derived monoclonal antibodies using its proprietary Reverse Translational Medicine™ (RTM™) technology platform. The milestone triggers a pre-agreed milestone payment to Neurimmune.
“We highly appreciate a key success in drug discovery of human-derived monoclonal antibodies with Neurimmune’s proprietary platform,” said Hiromu Habashita, Ph.D., Corporate Officer and Executive Director, Discovery and Research of Ono. “We believe this progress will lead to the delivery of a novel and innovative treatment for patients with neurodegenerative diseases.”
Ono will be responsible for worldwide development and marketing of products derived from this collaboration. Neurimmune is eligible to receive research fees, success-based milestones on the research and development progress, as well as royalties on product sales.